Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation
| Autor: | C M Hansen, E Binderup, K J Hamberg, L Binderup |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
Antineoplastic Agents Apoptosis Biology Pharmacology Seocalcitol Calcitriol In vivo Internal medicine Neoplasms Drug Discovery medicine Vitamin D and neurology Animals Humans Cell growth Cell Cycle Cancer Biological activity Cell Differentiation Cell cycle medicine.disease Endocrinology Drug Design Cancer cell |
| Zdroj: | Current pharmaceutical design. 6(7) |
| ISSN: | 1381-6128 |
| Popis: | It is well established that the metabolically active form of vitamin D, 1alpha,25-dihydroxyvitamin D 3 (1alpha,25(OH)2 D 3 ) plays a key role in the establishment and maintenance of the calcium metabolism in the body. In addition to this classic effect of 1alpha,25(OH)2 D 3 , substantial evidence has emerged demonstrating that 1alpha,25(OH)2 D 3 is able to regulate cell growth and differentiation in a number of different cell types, including cancer cells. However, the clinical usefulness of 1alpha,25(OH)2 D 3 is limited by its tendency to cause hypercalcaemia. Much effort has therefore been directed to identifying new vitamin D analogues with potent cell regulatory effects, but with weaker effects on the calcium metabolism than those of 1alpha,25(OH)2 D 3 . One of these new synthetic analogues is Seocalcitol (EB 1089). Despite being 50-200 times more potent than 1alpha,25(OH)2 D 3 with respect to regulation of cell growth and differentiation in vitro as well as in vivo, EB 1089 displays a reduced calcaemic activity in vivo compared to that of 1alpha,25(OH)2 D 3 . These characteristics make EB 1089 a potentially useful compound for the treatment of cancer. Recent clinical evaluation of EB 1089 has focused mainly on establishing a maximum tolerated dose in cancer patients. Early results confirm that the low calcaemic activity observed in animals can be reproduced in the clinic. Furthermore, EB 1089 has been shown to induce regression of tumours, especially in hepatocellular carcinoma where complete remission has been obtained. In conclusion, the development of EB 1089 as an anti-cancer drug holds promise. However, its final evaluation must await the completion of ongoing controlled clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|